159 related articles for article (PubMed ID: 26234400)
21. Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier.
Gan CW; Feng SS
Biomaterials; 2010 Oct; 31(30):7748-57. PubMed ID: 20673685
[TBL] [Abstract][Full Text] [Related]
22. Chimeric Nanoparticle: A Platform for Simultaneous Targeting of Phosphatidylinositol-3-Kinase Signaling and Damaging DNA in Cancer Cells.
Palvai S; More P; Mapara N; Basu S
ACS Appl Mater Interfaces; 2015 Aug; 7(33):18327-35. PubMed ID: 26258746
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
25. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
Harrington CF; Le Pla RC; Jones GD; Thomas AL; Farmer PB
Chem Res Toxicol; 2010 Aug; 23(8):1313-21. PubMed ID: 20666396
[TBL] [Abstract][Full Text] [Related]
26. Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes.
Silva H; Silva AC; Lemos FO; Monte-Neto RL; Fontes AP; Lopes MT; Frézard F
Anticancer Drugs; 2013 Feb; 24(2):131-9. PubMed ID: 23011234
[TBL] [Abstract][Full Text] [Related]
27. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
28. Reduced toxicological manifestations of cisplatin following encapsulation in folate grafted albumin nanoparticles.
Alam N; Dubey RD; Kumar A; Koul M; Sharma N; Sharma PR; Chandan BK; Singh SK; Singh G; Gupta PN
Life Sci; 2015 Dec; 142():76-85. PubMed ID: 26482203
[TBL] [Abstract][Full Text] [Related]
29. Cyclodextrin capped gold nanoparticles as a delivery vehicle for a prodrug of cisplatin.
Shi Y; Goodisman J; Dabrowiak JC
Inorg Chem; 2013 Aug; 52(16):9418-26. PubMed ID: 23889547
[TBL] [Abstract][Full Text] [Related]
30. A hybrid platinum drug dichloroacetate-platinum(II) overcomes cisplatin drug resistance through dual organelle targeting.
Zhang Y; Guo G; Ma B; Du R; Xiao H; Yang X; Li W; Gao Y; Li Y; Jing X
Anticancer Drugs; 2015 Aug; 26(7):698-705. PubMed ID: 25811961
[TBL] [Abstract][Full Text] [Related]
31. The prodrug platin-A: simultaneous release of cisplatin and aspirin.
Pathak RK; Marrache S; Choi JH; Berding TB; Dhar S
Angew Chem Int Ed Engl; 2014 Feb; 53(7):1963-7. PubMed ID: 24453035
[TBL] [Abstract][Full Text] [Related]
32. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
33. Protease-mediated release of chemotherapeutics from mesoporous silica nanoparticles to ex vivo human and mouse lung tumors.
van Rijt SH; Bölükbas DA; Argyo C; Datz S; Lindner M; Eickelberg O; Königshoff M; Bein T; Meiners S
ACS Nano; 2015 Mar; 9(3):2377-89. PubMed ID: 25703655
[TBL] [Abstract][Full Text] [Related]
34. Nanoparticle delivery of photosensitive Pt(IV) drugs for circumventing cisplatin cellular pathway and on-demand drug release.
Du R; Xiao H; Guo G; Jiang B; Yan X; Li W; Yang X; Zhang Y; Li Y; Jing X
Colloids Surf B Biointerfaces; 2014 Nov; 123():734-41. PubMed ID: 25454669
[TBL] [Abstract][Full Text] [Related]
35. Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents.
Wong DY; Yeo CH; Ang WH
Angew Chem Int Ed Engl; 2014 Jun; 53(26):6752-6. PubMed ID: 24844571
[TBL] [Abstract][Full Text] [Related]
36. Reduction-sensitive platinum (IV)-prodrug nano-sensitizer with an ultra-high drug loading for efficient chemo-radiotherapy of Pt-resistant cervical cancer in vivo.
Luo K; Guo W; Yu Y; Xu S; Zhou M; Xiang K; Niu K; Zhu X; Zhu G; An Z; Yu Q; Gan Z
J Control Release; 2020 Oct; 326():25-37. PubMed ID: 32531414
[TBL] [Abstract][Full Text] [Related]
37. Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys.
Working PK; Newman MS; Sullivan T; Brunner M; Podell M; Sahenk Z; Turner N
Toxicol Sci; 1998 Nov; 46(1):155-65. PubMed ID: 9928679
[TBL] [Abstract][Full Text] [Related]
38. Biodegradable polymeric system for cisplatin delivery: development, in vitro characterization and investigation of toxicity profile.
Alam N; Khare V; Dubey R; Saneja A; Kushwaha M; Singh G; Sharma N; Chandan B; Gupta PN
Mater Sci Eng C Mater Biol Appl; 2014 May; 38():85-93. PubMed ID: 24656356
[TBL] [Abstract][Full Text] [Related]
39. An Iron Oxide Nanocarrier Loaded with a Pt(IV) Prodrug and Immunostimulatory dsRNA for Combining Complementary Cancer Killing Effects.
Hernández-Gil J; Cobaleda-Siles M; Zabaleta A; Salassa L; Calvo J; Mareque-Rivas JC
Adv Healthc Mater; 2015 May; 4(7):1034-42. PubMed ID: 25846677
[TBL] [Abstract][Full Text] [Related]
40. A Pt(IV)-conjugated brain penetrant macrocyclic peptide shows pre-clinical efficacy in glioblastoma.
Jimenez-Macias JL; Lee YC; Miller E; Finkelberg T; Zdioruk M; Berger G; Farquhar CE; Nowicki MO; Cho CF; Fedeles BI; Loas A; Pentelute BL; Lawler SE
J Control Release; 2022 Dec; 352():623-636. PubMed ID: 36349615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
